GSK invests $300m in 23andMe under drug development deal
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research and development for new medicines…
GSK
-
-
GSK gets priority review for Krintafel to prevent malaria relapse
GlaxoSmithKline (GSK) has gained the US Food and Drug Administration (FDA) priority review approval for its Krintafel (tafenoquine) to prevent…
-
GSK to divest tapinarof asset rights to Dermavant for £250m
GlaxoSmithKline (GSK) has signed an agreement to divest rights to tapinarof, one of its investigational drugs, to Dermavant Sciences, a…
